BRPI0509464A - compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos - Google Patents

compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos

Info

Publication number
BRPI0509464A
BRPI0509464A BRPI0509464-0A BRPI0509464A BRPI0509464A BR PI0509464 A BRPI0509464 A BR PI0509464A BR PI0509464 A BRPI0509464 A BR PI0509464A BR PI0509464 A BRPI0509464 A BR PI0509464A
Authority
BR
Brazil
Prior art keywords
treatment
compounds
neurodegenerative disorders
sulfonamide compounds
formula
Prior art date
Application number
BRPI0509464-0A
Other languages
English (en)
Inventor
Lei Zhang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0509464A publication Critical patent/BRPI0509464A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS TIAZOL SULFONAMIDA PARA O TRATAMENTO DE DISTúRBIOS NEURODEGENERATIVOS". A presente invenção refere-se a compostos da Fórmula (1) onde R1, R2, R3, R4, m, n e p são conforme definido. Compostos da Fórmula (1) têm atividade de inibição da produção de peptídeo AB. A invenção refere-se também a composições farmacêuticas e métodos para tratamento de doenças, por exemplo, doenças neurodegenerativas, por exemplo, doença de Alzheimer, em um mamífero compreendendo compostos da Fórmula (1).
BRPI0509464-0A 2004-04-01 2005-03-29 compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos BRPI0509464A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55862704P 2004-04-01 2004-04-01
PCT/US2005/010264 WO2005097114A2 (en) 2004-04-01 2005-03-29 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BRPI0509464A true BRPI0509464A (pt) 2007-09-11

Family

ID=35125602

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509464-0A BRPI0509464A (pt) 2004-04-01 2005-03-29 compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos

Country Status (7)

Country Link
US (2) US7309709B2 (pt)
EP (1) EP1734957A4 (pt)
JP (1) JP2007530699A (pt)
BR (1) BRPI0509464A (pt)
CA (1) CA2561928A1 (pt)
MX (1) MXPA06011349A (pt)
WO (1) WO2005097114A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1730119T3 (da) * 2004-03-23 2008-08-11 Pfizer Prod Inc Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
US7309709B2 (en) * 2004-04-01 2007-12-18 Pfizer Inc. Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
AU2006293619A1 (en) * 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
MX2011011428A (es) * 2009-05-01 2011-11-29 Raqualia Pharma Inc Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
CN116531373B (zh) * 2022-01-26 2025-02-25 上海日馨医药科技股份有限公司 噻唑类化合物、其药物组合物及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006151A (en) * 1973-09-21 1977-02-01 Polaroid Corporation Precursors of β-aza-disubstituted amino styryl dyes
SK20052000A3 (sk) * 1998-06-30 2002-08-06 Pfizer Products Inc. Nepeptidové inhibítory VLA-4 dependentnej bunkovej väzby použiteľné pri liečení zápalových, autoimunitných a respiračných chorôb
WO2001081316A2 (en) * 2000-04-27 2001-11-01 Abbott Laboratories Substituted phenyl farnesyltransferase inhibitors
WO2003040086A1 (en) * 2001-11-09 2003-05-15 Kissei Pharmaceutical Co., Ltd. 5-amidino-2-hydroxybenzenesulfonamide derivatives, medicinal compositions containing the same, medicinal use thereof and intermediates in the production thereof
AU2003262073A1 (en) * 2002-09-20 2004-04-08 Tsumura And Co. Antitussives
US7309709B2 (en) * 2004-04-01 2007-12-18 Pfizer Inc. Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
EP1734957A4 (en) 2009-06-17
US20080108675A1 (en) 2008-05-08
MXPA06011349A (es) 2007-03-21
JP2007530699A (ja) 2007-11-01
WO2005097114A3 (en) 2006-08-24
EP1734957A2 (en) 2006-12-27
US20050222223A1 (en) 2005-10-06
WO2005097114A2 (en) 2005-10-20
US7309709B2 (en) 2007-12-18
CA2561928A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
BRPI0413709A (pt) compostos para o tratamento de distúrbios neurodegenerativos
BRPI0409721A (pt) compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
BRPI0509504A (pt) compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
BRPI0509464A (pt) compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos
NO20081845L (no) Imidazolforbindelser for behandling av neurologiske lidelser
WO2005016267A3 (en) Oxazole compounds for the treatment of neurodegenerative disorders
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
BRPI0509582A (pt) compostos de tiazol-amina e respectivas composições farmacêuticas
BRPI0509386A (pt) compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
CU23591B7 (es) Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.